Amgen, Inc.
šŗšøUnited States
- Country
- šŗšøUnited States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-07-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 850
- Registration Number
- NCT00156962
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 182
- Registration Number
- NCT00141921
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 241
- Registration Number
- NCT00131638
Treatment for Subjects With Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117897
Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117234
Study of Transplant Related Anemia Treated With AranespĀ® (STRATA)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117065
Study to Evaluate Effectiveness of AranespĀ®
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117130
Anakinra (KineretĀ®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117091
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 313
- Registration Number
- NCT00116688
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 5103
- Registration Number
- NCT00116727
Ā© Copyright 2024. All Rights Reserved by MedPath